Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

ClinicalTrials.gov ID: NCT00743652

Public ClinicalTrials.gov record NCT00743652. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.

Study identification

NCT ID: NCT00743652
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Pfizer; Industry
Enrollment: 373 participants

Conditions and interventions

Conditions

Interventions

13-valent Pneumococcal Conjugate Vaccine Biological

Biological

Eligibility (public fields only)

Age range: 42 Days to 5 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2009 (Type not available)
Primary completion: Sep 2010 (Actual)
Completion: Sep 2010 (Actual)
Last update posted: Mar 15, 2012

2009 – 2010

United States locations

U.S. sites: 21
U.S. states: 1
U.S. cities: 21

Facility	City	State	ZIP	Site status
Pfizer Investigational Site	Akiak	Alaska	99552	—
Pfizer Investigational Site	Bethel	Alaska	99559	—
Pfizer Investigational Site	Chefornak	Alaska	99561	—
Pfizer Investigational Site	Chevak	Alaska	99563	—
Pfizer Investigational Site	Eek	Alaska	99578	—
Pfizer Investigational Site	Emmonak	Alaska	99581	—
Pfizer Investigational Site	Hooper Bay	Alaska	99604	—
Pfizer Investigational Site	Kalskag	Alaska	99607	—
Pfizer Investigational Site	Kasigluk	Alaska	99609	—
Pfizer Investigational Site	Kongiganak	Alaska	99545	—
Pfizer Investigational Site	Kotlik	Alaska	99620	—
Pfizer Investigational Site	Kwethluk	Alaska	99621	—
Pfizer Investigational Site	Kwigillingok	Alaska	99622	—
Pfizer Investigational Site	Mountain Village	Alaska	99632	—
Pfizer Investigational Site	Napaskiak	Alaska	99559	—
Pfizer Investigational Site	Newtok	Alaska	99559	—
Pfizer Investigational Site	Nunapitchuk	Alaska	99641	—
Pfizer Investigational Site	Russian Mission	Alaska	99657	—
Pfizer Investigational Site	Scammon Bay	Alaska	99662	—
Pfizer Investigational Site	Toksook Bay	Alaska	99637	—
Pfizer Investigational Site	Tuluksak	Alaska	99679	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00743652, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 15, 2012 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00743652 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →